FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1579-1580 November 22, 2001 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

(American Heart Association Monograph Series.) Edited by Jesse E. Adams III, with Fred S. Apple, Allan S. Jaffe, and Alan H.B. Wu. 272 pp. Armonk, N.Y., Futura, 2001. $79. ISBN 0-87993-472-7.

Interest in biochemical markers in cardiology has increased tremendously in the past decade. Previously, biochemical markers were used mainly for retrospective verification of acute myocardial infarction. However, as more specific and sensitive markers of myocardial damage (e.g., troponin T and I) have become available, the focus has shifted to early diagnosis of myocardial damage, risk stratification, and selection of treatment. Furthermore, biochemical markers in cardiology are no longer equivalent to markers of myocardial damage. Markers of inflammation (e.g., C-reactive protein) and cardiac dysfunction (e.g., the natriuretic peptides) are already used in clinical practice. Markers of coronary artery disease, ischemia, and . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.